Masliah E, Iwai A, Mallory M, Uéda K, Saitoh T
Department of Neurosciences, University of California-San Diego School of Medicine, La Jolla 92093-0624, USA.
Am J Pathol. 1996 Jan;148(1):201-10.
We have recently identified, in the brain tissue of patients afflicted with Alzheimer's disease (AD), the non-A beta component of AD amyloid (NAC) as a new constituent of amyloid. NAC is derived from a larger precursor, NACP, a presynaptic protein. To better understand the role of NACP/NAC in the pathogenesis of AD, we used semiquantitative immunoblotting and combined double-immunocytochemistry/laser scanning confocal microscopy to study the concentration and distribution of NACP/NAC in human brain, and compared them to the concentration and distribution of the presynaptic marker synaptophysin and the amyloid marker A beta. The semiquantitative immunoblotting demonstrated that the NACP concentration is slightly increased in the AD frontal cortex without statistical significance, whereas synaptophysin was reduced in its levels in AD. Consequently the proportion of NACP/synaptophysin was more than double in the AD frontal cortex as compared with controls. In the AD neocortex, NACP was colocalized with approximately 80% of the synaptophysin-immunoreactive structures (presumably the presynaptic terminals) and with the dystrophic neuritic component of the plaques. Computer-aided analysis showed that numbers of NACP-immunoreactive structures along synaptophysin-immunoreactive structures were significantly diminished (30 to 40%) in AD. Although the overall numbers of NACP-positive structures were decreased, there was a significant increase in the intensity of NACP-immunoreactivity per structure in AD. This increased intensity of NACP immunoreactivity per structure in AD was not observed with anti-synaptophysin, consistent with immunoblotting-based quantification. Antibodies against NAC immunoreacted with amyloid in 35% of the diffuse plaques and 55% of the mature plaques. Normal aged control brains containing small groups of diffuse plaques were negative with anti-NAC. Double-immunolabeling studies with A beta antibodies showed that NAC immunoreactivity is more abundant in the center portion of amyloid rather than in the periphery. These studies suggest that there is a connection between metabolism of presynaptic proteins and amyloid formation, and that NAC might follow diffuse A beta accumulation resulting in the formation of compact amyloid and mature plaques.
我们最近在阿尔茨海默病(AD)患者的脑组织中,确定了AD淀粉样蛋白的非Aβ成分(NAC)是淀粉样蛋白的一种新成分。NAC来源于一种更大的前体NACP,一种突触前蛋白。为了更好地理解NACP/NAC在AD发病机制中的作用,我们使用半定量免疫印迹法以及联合双免疫细胞化学/激光扫描共聚焦显微镜技术,研究了NACP/NAC在人脑中的浓度和分布,并将其与突触前标志物突触素以及淀粉样蛋白标志物Aβ的浓度和分布进行比较。半定量免疫印迹法显示,AD额叶皮质中NACP浓度略有升高,但无统计学意义,而AD中突触素水平降低。因此,与对照组相比,AD额叶皮质中NACP/突触素的比例增加了一倍多。在AD新皮质中,NACP与大约80%的突触素免疫反应性结构(可能是突触前终末)以及斑块的营养不良性神经突成分共定位。计算机辅助分析显示,AD中沿着突触素免疫反应性结构的NACP免疫反应性结构数量显著减少(30%至40%)。尽管NACP阳性结构的总数减少,但AD中每个结构的NACP免疫反应强度显著增加。用抗突触素抗体未观察到AD中每个结构的NACP免疫反应强度增加,这与基于免疫印迹的定量结果一致。抗NAC抗体在35%的弥漫性斑块和55%的成熟斑块中与淀粉样蛋白发生反应。含有少量弥漫性斑块的正常老年对照脑对抗NAC呈阴性。用Aβ抗体进行的双免疫标记研究表明,NAC免疫反应性在淀粉样蛋白的中心部分比周边部分更丰富。这些研究表明,突触前蛋白代谢与淀粉样蛋白形成之间存在联系,并且NAC可能在弥漫性Aβ积累之后出现,导致致密淀粉样蛋白和成熟斑块的形成。